Imunon, Inc. (IMNN)

NASDAQ: IMNN · IEX Real-Time Price · USD
1.60
-0.15 (-8.57%)
At close: Sep 23, 2022 4:00 PM
1.67
+0.07 (4.37%)
After-hours: Sep 23, 2022 7:58 PM EDT
-8.57%
Market Cap 11.36M
Revenue (ttm) 500,000
Net Income (ttm) -26.15M
Shares Out 7.10M
EPS (ttm) -3.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 47,565
Open 1.71
Previous Close 1.75
Day's Range 1.55 - 1.71
52-Week Range 1.55 - 15.75
Beta 2.26
Analysts n/a
Price Target n/a
Earnings Date n/a

About IMNN

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunoth... [Read more...]

Industry Biotechnology
IPO Date Mar 5, 1985
CEO Michael Tardugno
Employees 29
Stock Exchange NASDAQ
Ticker Symbol IMNN
Full Company Profile

Financial Performance

In 2021, Imunon's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$20.77 million, -3.32% less than in 2020.

Financial Statements

News

Celsion Corporation Announces Company Name Change to Imunon, Inc.

New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines

Other symbols: CLSN
5 days ago - GlobeNewsWire

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone

Other symbols: CLSN
1 week ago - GlobeNewsWire

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30...

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive O...

Other symbols: CLSN
1 week ago - GlobeNewsWire

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Execut...

Other symbols: CLSN
2 weeks ago - GlobeNewsWire

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model

Other symbols: CLSN
3 weeks ago - GlobeNewsWire

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT

Other symbols: CLSN
1 month ago - GlobeNewsWire

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, Augu...

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...

Other symbols: CLSN
1 month ago - GlobeNewsWire

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that ...

Other symbols: CLSN
2 months ago - GlobeNewsWire

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Michael H. Tardugno appointed Executive Chairman of the Board

Other symbols: CLSN
2 months ago - GlobeNewsWire

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Por...

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit

Other symbols: CLSN
3 months ago - GlobeNewsWire

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT

Other symbols: CLSN
4 months ago - GlobeNewsWire

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies

Other symbols: CLSN
4 months ago - GlobeNewsWire

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 1...

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced...

Other symbols: CLSN
4 months ago - GlobeNewsWire

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccin...

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus

Other symbols: CLSN
5 months ago - GlobeNewsWire

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer ...

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng

Other symbols: CLSN
5 months ago - GlobeNewsWire

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it wo...

Other symbols: CLSN
5 months ago - GlobeNewsWire

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering ...

Other symbols: CLSN
5 months ago - GlobeNewsWire

Why Celsion Shares Are Pulling Back Today

Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. What To Know: The offering com...

Other symbols: CLSN
5 months ago - Benzinga

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Canc...

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA

Other symbols: CLSN
5 months ago - GlobeNewsWire

CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional invest...

Other symbols: CLSN
5 months ago - GlobeNewsWire

Why Celsion Stock Is Surging Today

Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the bus...

Other symbols: CLSN
5 months ago - Benzinga

Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the ...

Other symbols: CLSN
5 months ago - GlobeNewsWire

Celsion Corporation Reports 2021 Financial Results and Provides Business Update

Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time

Other symbols: CLSN
5 months ago - GlobeNewsWire

Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31...

LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announc...

Other symbols: CLSN
6 months ago - GlobeNewsWire

Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses

Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024

Other symbols: CLSN
6 months ago - GlobeNewsWire